Holen Sie sich die Stockscreener-App
0.9158
3.89%
0.0343
Handel nachbörslich:
.93
0.0142
+1.55%
Schlusskurs vom Vortag:
$0.8815
Offen:
$0.8814
24-Stunden-Volumen:
433.01K
Relative Volume:
1.24
Marktkapitalisierung:
$41.30M
Einnahmen:
$1.12M
Nettoeinkommen (Verlust:
$-11.17M
KGV:
-2.8972
EPS:
-0.3161
Netto-Cashflow:
$-10.98M
1W Leistung:
+13.64%
1M Leistung:
+6.91%
6M Leistung:
+3.34%
1J Leistung:
-23.04%
1-Tages-Spanne:
$0.8421
$0.94
1-Wochen-Bereich:
$0.7901
$0.94
52-Wochen-Spanne:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.9158 | 39.75M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting - Investing News Network
RenovoRx reports pharmacokinetic data from pancreatic trial By Investing.com - Investing.com Canada
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - The Manila Times
Pancreatic cancer study tests drug delivery that may cut side effects - Stock Titan
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss; Stock Holds SteadyCrowd Stock Picks - Newser
RenovoRx Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues Clinical DevelopmentNet Income Trends - Newser
RenovoRx Inc. (RNXT) Hovers Near Support as Thin Trading PersistsExpert Momentum Signals - Newser
RenovoRx (RNXT) Slides to $0.88, Nearing Critical SupportRetail Driven Moves - Newser
RenovoRx CFO Mark Voll buys $19,690 in common stock - Investing.com India
RenovoRx (RNXT) Q1 2026 Results Trail Estimates: A Deeper LookGuidance Accuracy Score - Newser
RenovoRx CFO Mark Voll buys $19,690 in common stock By Investing.com - Investing.com South Africa
RenovoRx (RNXT) CFO adds 25,000 shares, lifting direct stake to 142,380 - Stock Titan
RNXT: Targeted chemo delivery platform drives revenue growth and nears key clinical milestones - TradingView
RNXT: Targeted drug delivery platform drives revenue growth and nears key clinical milestones - TradingView
RenovoRx (RNXT) Q1 2026 Results Miss Estimates — EPS $-0.09 vs $-0.08Working Capital - Newser
RenovoRx Earnings Call Signals Commercial Inflection - TipRanks
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th - Investing News Network
RenovoRx (RNXT) Q1 2026 Earnings Transcript - The Globe and Mail
RenovoRx to highlight record RenovoCath revenue, pancreatic cancer trial timing - Stock Titan
RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates - MSN
RenovoRx, Inc. (RNXT) may report negative earnings: Know the trend ahead of next week's release - MSN
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail
RenovoRx, Inc. 2025 Annual Report 10-K/A — Key Risks, Regulatory Challenges, and Strategic Focus in Drug Development 15 - Minichart
RenovoRx (RNXT) details control remediation and high clinical, cash risks - Stock Titan
JonesTrading Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Should You Sell RenovoRx (RNXT) After -4.21% Drop? 2026-05-15Trading Ideas - newser.com
RenovoRx (RNXT) Q1 2026 Earnings: EPS $-0.08 Beats EstimatesPut/Call Ratio - Newser
A. G. P. Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter - The Manila Times
RNXT: Company Confident in Cash Reserves to Sustain Operations U - GuruFocus
RNXT Reports Strong Q1 Revenue Surpassing Expectations - GuruFocus
RenovoRx earnings missed, revenue topped estimates By Investing.com - Investing.com Canada
Earnings call transcript: RenovoRx Q1 2026 revenue beats forecast, stock rises - Investing.com
RNXT: Q1 2026 revenue surged 136% sequentially, fueled by commercial center expansion and strong margins - TradingView
RenovoRx Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RNXT: Record Q1 revenue and rapid center expansion position the company for strong 2026 growth - TradingView
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
RenovoRx (NASDAQ: RNXT) Q1 2026 revenue jumps as TIGeR-PaC nears full enrollment - Stock Titan
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Record Q1 2026 revenue and TIGeR-PaC progress at RenovoRx (NASDAQ: RNXT) - Stock Titan
RenovoRx, Inc. Reiterates Earnings Guidance for 2026 - marketscreener.com
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates - MSN
TradingKey - TradingKey
What RenovoRx (RNXT) is doing to stay ahead (Weakens) 2026-05-08Early Entry - newser.com
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
RNXT: RenovoCath's targeted delivery platform drives adoption, revenue growth, and promising clinical results - TradingView
Is RenovoRx (RNXT) stock creating a trading range | RenovoRx beats EPS by 2%, posts narrower Q4 lossEarnings Expansion Phase - Newser
RenovoRx (RNXT) 2026 proxy: board elections, equity pool increase and auditor vote - Stock Titan
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):